Clinicopathological and prognostic significance of programmed death ligand-1 expression in breast cancer: a meta-analysis

Kim, Hye Min; Lee, Jinae; Koo, Ja Seung

doi:10.1186/s12885-017-3670-1

Cited by 45 publications

(36 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Results from two meta‐analyses including partially overlapping studies confirmed the greater PD‐L1 expression in TNBC compared with non‐TN subtypes but were not consistent in reporting the association between HER2 status and PD‐L1 expression.…”

Section: Methodsmentioning

confidence: 88%

“…A possible explanation for such observations may be attributable to the immune escape phenomenon. Indeed, a high expression of PD‐L1 may reflect the activation of the immune checkpoint PD1/PD‐L1 pathway leading to the mitigation of the host's antitumor immune response, thus ultimately resulting in increased tumor aggressiveness . Although intriguing, further evidence is needed in order to confirm this hypothesis.…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Programmed Cell Death Ligand 1 in Breast Cancer: Technical Aspects, Prognostic Implications, and Predictive Value

2019

View full text Add to dashboard Cite

In the light of recent advances in the immunotherapy field for breast cancer (BC) treatment, especially in the triple‐negative subtype, the identification of reliable biomarkers capable of improving patient selection is paramount, because only a portion of patients seem to derive benefit from this appealing treatment strategy. In this context, the role of programmed cell death ligand 1 (PD‐L1) as a potential prognostic and/or predictive biomarker has been intensively explored, with controversial results. The aim of the present review is to collect available evidence on the biological relevance and clinical utility of PD‐L1 expression in BC, with particular emphasis on technical aspects, prognostic implications, and predictive value of this promising biomarker. Implications for Practice In the light of the promising results coming from trials of immune checkpoint inhibitors for breast cancer treatment, the potential predictive and/or prognostic role of programmed cell death ligand 1 (PD‐L1) in breast cancer has gained increasing interest. This review provides clinicians with an overview of the available clinical evidence regarding PD‐L1 as a biomarker in breast cancer, focusing on both data with a possible direct impact on clinic and methodological pitfalls that need to be addressed in order to optimize PD‐L1 implementation as a clinically useful tool for breast cancer management.

show abstract

Section: Methodsmentioning

confidence: 88%

Section: Methodsmentioning

confidence: 99%

Programmed Cell Death Ligand 1 in Breast Cancer: Technical Aspects, Prognostic Implications, and Predictive Value

2019

View full text Add to dashboard Cite

show abstract

“…Both findings are linked to a better clinical outcome as proven from the studies mentioned above. Many studies have been conducted in order to evaluate the prognostic value of PDL1TC, PDL1IC and TILs in IBC, and even after many meta-analyses some results remain conflicting (41,59,60). Kim et al (60), conducted an meta-analysis which included 7,877 cases and was led to the conclusion that PDL1TC expression is associated with poorer DFS.…”

Section: Figure 1 (A) Pd-l1 Expression In Tumor Cells (×20) (B) Pd-mentioning

confidence: 99%

PD-L1 Expression and Tumor-infiltrating Lymphocytes in Breast Cancer: Clinicopathological Analysis in Women Younger than 40 Years Old

Evangelou

Papoudou‐Bai

Karpathiou

et al. 2020

In Vivo

View full text Add to dashboard Cite

Background/Aim: To evaluate the association between programmed cell death ligand 1 (PD-L1) expression on both tumor cells (TC) and inflammatory cells (IC), tumor infiltrating lymphocytes (TILs), CD3 + and CD8 + lymphocytes and other clinicopathological parameters in primary infiltrative breast cancer (IBC) of young women, a population shown to have a worse prognosis. Materials andMethods: A retrospective study was performed collecting data from patients younger than 40 years old. Forty-five young women with IBC were included. Whole tissue sections were used to evaluate all parameters. Results: Twenty percent (20%) of cases showed PD-L1 expression by tumor cells (PDL1TC) and 44.4% showed PD-L1 expression by immune cells (PDL1IC). Furthermore, 28.88% revealed high stromal TILs. PDL1TC and PDL1IC expression were significantly associated with tumor diameter and expression of estrogen (ER) and progesterone (PR) receptors and Ki67. PDL1TC expression was also associated with grade. High TILs were associated with tumor diameter, ER and Ki67 expression. PDL1TC, PDL1IC expression and TILs were associated with the density of CD3 + and CD8 + lymphocytes. Conclusion: Our results are similar to those of other age groups, as reported in the literature.

show abstract

“…The fact that cancer cells upregulate PD-L1 expression in response to virus infection is of importance as several meta-analysis studies have shown that PD-L1 expression is of prognostic value in multiple types of cancer including TNBC and could help clinicians to discriminate patients who will and will not respond to therapeutics targeting PD-1/PD-L1 interaction. [47][48][49][50] Recently there has been a growing interest in combining different types of OVs with ICIs to improve therapeutic efficacy. 41 A study published by Bourgeois-Daigneault et al tested oncolytic Maraba virus in neo-adjuvant setting in TNBC models where they found that their OV sensitized the otherwise refractory tumors to ICIs.…”

Section: Discussionmentioning

confidence: 99%

Oncolytic poxvirus CF33-hNIS-ΔF14.5 favorably modulates tumor immune microenvironment and works synergistically with anti-PD-L1 antibody in a triple-negative breast cancer model

et al. 2020

View full text Add to dashboard Cite

Triple-negative breast cancer is the most aggressive subtype of breast cancer and is difficult to treat. Breast cancer is considered to be poorly immunogenic and hence is less responsive to immunotherapies. We tested whether the oncolytic poxvirus CF33-hNIS-ΔF14.5 could modulate tumor immune microenvironment and make the tumors responsive to the immune checkpoint inhibitor anti-PD-L1. We found that virus infection causes the upregulation of PD-L1 levels on triple-negative breast cancer cells in vitro as well as in vivo in mice. In a mouse model of orthotopic triple-negative breast cancer, the virus was found to increase tumor infiltration by CD8+ T cells. Likewise, in mice treated with CF33-hNIS-ΔF14.5 high levels of proinflammatory cytokines IFNγ and IL-6 were found in the tumors but not in the serum. The levels of immune modulation were even higher in mice that were treated with a combination of the virus and anti-PD-L1 antibody. While CF33-hNIS-ΔF14.5 and anti-PD-L1 antibody failed to exert significant anti-tumor effect as a single agent, a combination of the two agents resulted in significant antitumor effect with 50% mice experiencing complete tumor regression when both agents were injected intra-tumorally. Furthermore, the 'cured' mice did not develop tumor after re-challenge with the same cancer cells suggesting that they developed immunity against those cancer cells. Taken together, our study shows that CF33-hNIS-ΔF14.5 favorably modulates tumor immune microenvironment in triplenegative breast cancer model making them responsive to the immune checkpoint inhibitor anti-PD-L1, and hence warrants further studies to determine the clinical applicability of this combination therapy.

show abstract

Clinicopathological and prognostic significance of programmed death ligand-1 expression in breast cancer: a meta-analysis

Cited by 45 publications

References 44 publications

Programmed Cell Death Ligand 1 in Breast Cancer: Technical Aspects, Prognostic Implications, and Predictive Value

Programmed Cell Death Ligand 1 in Breast Cancer: Technical Aspects, Prognostic Implications, and Predictive Value

PD-L1 Expression and Tumor-infiltrating Lymphocytes in Breast Cancer: Clinicopathological Analysis in Women Younger than 40 Years Old

Oncolytic poxvirus CF33-hNIS-ΔF14.5 favorably modulates tumor immune microenvironment and works synergistically with anti-PD-L1 antibody in a triple-negative breast cancer model

Contact Info

Product

Resources

About